Corrections and Update Log

Affected: All pages describing the tirzepatide shortage timeline

What we said: We wrote that the tirzepatide shortage was declared resolved in October 2024, as a single settled event.

What it now says: FDA determined the shortage resolved on 2 October 2024. On 22 October 2024 that decision was remanded to the agency for reevaluation as part of litigation. On 5 March 2025 a district court denied the plaintiffs' preliminary injunction in Outsourcing Facilities Association v. FDA. Some sources date the resolution to December 2024 for that reason.

Why it was wrong: We compressed a contested twelve-month sequence into one date. The litigation is material context for anyone assessing how settled the current regulatory position is.

Source: FDA drug shortage record EV-0805

Affected: All pages showing a tirzepatide titration schedule

What we said: We published a fixed week-by-week escalation calendar: 2.5 mg for weeks 1–4, 5 mg for weeks 5–8, 7.5 mg for weeks 9–12, and so on through 15 mg by week 21.

What it now says: The Zepbound label directs 2.5 mg once weekly for 4 weeks, an increase to 5 mg, then increases in 2.5 mg increments no sooner than every 4 weeks based on tolerability and response, to a maximum of 15 mg. It names 5, 10 and 15 mg as the recommended maintenance dosages; 7.5 and 12.5 mg are titration steps.

Why it was wrong: We had taken the schedule from a secondary summary rather than the label. Presenting a minimum interval as a calendar implies escalation is automatic. On a page about dosing, that is the wrong impression to leave.

Source: ZEPBOUND US Prescribing Information EV-0701

Affected: All pharmacy verification pages referencing 503B facilities

What we said: We wrote that 503B outsourcing facilities must comply with CGMP, in a context implying that registration demonstrated compliance.

What it now says: CGMP compliance is a legal requirement under section 503B. FDA states separately that registration means only that the agency received the required information — it does not mean the facility is making FDA-approved drugs, and it does not mean it is in compliance with CGMP.

Why it was wrong: Our wording let a legal requirement carry the weight of a verified fact. The useful question is whether a facility has been inspected and what the inspection found.

Source: FDA — Questions and Answers: Outsourcing Facility Registration EV-0601

Affected: All pages comparing the $149 FDA-approved oral options against compounded programmes

What we said: We reported that the cheapest FDA-approved GLP-1 is now $149 a month and undercuts most of the compounded market, without stating the efficacy of the products being compared.

What it now says: The same pages now carry the efficacy ladder. Orforglipron reported approximately 11–12.4% mean reduction in ATTAIN-1 and oral semaglutide 13.6–16.6% in OASIS 4, against about 20.9% for tirzepatide 15 mg in SURMOUNT-1. Both $149 options are the least effective approved products.

Why it was wrong: The price statement was accurate and the comparison was incomplete. Comparing a roughly 12% drug with a roughly 21% drug on price alone is the error this publication exists to catch.

Source: ATTAIN-1, OASIS 4 and SURMOUNT-1 EV-0113

GLP-1 Tirzepatide Review. “Corrections and Update Log.” S.J Partners LLC, 2026-07-24. https://glp1tirzepatidereview.com/corrections/

When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.